A5072400207- Thyroid Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Adrenal and Paraganglionic Tumors
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Pituitary Gland Disorders and Treatments
- Cancer, Hypoxia, and Metabolism
- Thyroid and Parathyroid Surgery
- Hormonal Regulation and Hypertension
- Glioma Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Lung Cancer Treatments and Mutations
- BRCA gene mutations in cancer
- Head and Neck Anomalies
- Cancer Immunotherapy and Biomarkers
- Bone health and treatments
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Management of metastatic bone disease
- Gestational Trophoblastic Disease Studies
- Uterine Myomas and Treatments
- Renal cell carcinoma treatment
- Sarcoma Diagnosis and Treatment
- Brain Metastases and Treatment
- Microtubule and mitosis dynamics
Institut Gustave Roussy
2016-2025
Université Paris-Saclay
2017-2025
Laboratoire d'études sur les monothéismes
2018-2022
Inserm
2013-2019
Université Paris-Sud
2016-2019
Délégation Paris 5
2012-2019
Université Paris Cité
2012-2019
Hôpital Paul-Brousse
2014-2015
Centre National de la Recherche Scientifique
2014-2015
Observatoire de la Côte d’Azur
2014
The new WHO classification of gastroenteropancreatic (GEP) neuroendocrine tumors (NET) implies that G3 neoplasms with mitotic index >20 and/or Ki67 >20% are carcinomas (NEC), described as poorly differentiated, small or large cell types, by analogy lung NEC. To characterize the subgroup non-small-cell-type GEP and thoracic NET according to their pathological features, response cisplatin overall survival (OS). We reviewed clinical presentation referred our institution for 5 years. Data from...
Abstract Purpose: KEYNOTE-158 (ClinicalTrials.gov identifier: NCT02628067) investigated the efficacy and safety of pembrolizumab across multiple cancers. We present results from patients with previously treated advanced well-differentiated neuroendocrine tumors (NET). Patients Methods: Pembrolizumab 200 mg was administered every 3 weeks for 2 years or until progression, intolerable toxicity, physician/patient decision. Tumor imaging performed 9 first year then 12 weeks. Endpoints included...
Changes in the management of patients with cancer and delays treatment delivery during COVID-19 pandemic may impact use hospital resources mortality.Patient flows, patient pathways were simulated using a discrete event simulation model patient-level data from large French comprehensive centre's discharge database, considering two scenarios delays: massive return November 2020 (early-return) or March 2021 (late-return). Expected additional deaths at 5 years mortality rate estimated individual...
Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in advanced RET-mutant medullary thyroid cancer phase 1–2 trial, but its as compared with approved multikinase inhibitors is unclear. Download PDF of the Research Summary. We conducted 3, randomized trial comparing selpercatinib first-line therapy physician's choice cabozantinib or vandetanib (control group). Eligible patients had progressive disease documented within 14 months before enrollment. The primary end...
Cyclophosphamide–dacarbazine–vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine only recognized active drug in neuroendocrine tumours. We investigated therapeutic benefit temozolomide (TMZ), an oral alternative to dacarbazine, patients with MPP. This a retrospective study consecutive documented progressive examined correlation between Succinate dehydrogenase B ( SDHB ) mutation O(6)‐methylguanine‐DNA...
There is no standard for second-line chemotherapy in poorly differentiated grade 3 neuroendocrine carcinoma (G3-NEC) patients. We analyzed the antitumor efficacy of 5-fluorouracil and oxaliplatin (FOLFOX) this population. A single-center retrospective analysis consecutive G3-NEC patients treated with FOLFOX after failure a cisplatinum-based regimen between December 2003 June 2012 was performed. Progression-free survival (PFS), overall (OS), response rate, safety were assessed according to...
Patients with cancer are presumed to be at increased risk of severe COVID-19 outcomes due underlying malignancy and treatment-induced immunosuppression. Of the first 178 patients managed for Gustave Roussy Cancer Centre, 125 (70.2%) were hospitalized, 47 (26.4%) developed clinical worsening 31 (17.4%) died. An age over 70 years, smoking status, metastatic disease, cytotoxic chemotherapy an Eastern Cooperative Oncology Group score ≥2 last visit strongest determinants death. In multivariable...
Abstract Context Pheochromocytomas and paragangliomas (PPGLs) are characterized by a strong genetic component, with up to 40% of patients carrying germline mutation in PPGL susceptibility gene. International guidelines recommend that screening be proposed all PPGL. Objective Our objective was evaluate how positive test impacts the management outcome SDHx or VHL-related Design We performed multicentric retrospective study involving 221 propositi an SDHB, SDHD, SDHC, VHL mutation. Patients...
Abstract Background The authors report results from the thyroid carcinoma cohort of multicohort phase 2 KEYNOTE‐158 study (NCT02628067), which evaluated pembrolizumab monotherapy in patients with previously treated cancers. Methods Eligible had histologically and/or cytologically confirmed papillary or follicular carcinoma, failure intolerance to prior therapy, and measurable disease per Response Evaluation Criteria Solid Tumors (RECIST) v1.1. Patients received (200 mg) every 3 weeks for up...
Background: Rearranged during transfection (RET) alterations are targetable oncogenic drivers in thyroid cancer. Primary data from the open-label, phase 1/2 ARROW study demonstrated clinical activity and manageable safety with pralsetinib, a selective RET inhibitor, patients advanced/metastatic RET-altered We present an updated analysis more longer follow-up. Methods: Adult RET-mutant medullary cancer (MTC) or fusion-positive who initiated oral pralsetinib at 400 mg once daily were included....
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported. LIBRETTO-001 is a registrational phase I/II, single-arm, open-label study of selpercatinib patients with RET...
Purpose: The prognostic importance of RET and RAS mutations their relationship to clinicopathologic parameters outcomes in medullary thyroid carcinoma (MTC) need be clarified.
PURPOSE High-risk clonal hematopoiesis (CH) is frequently incidentally found in patients with solid tumors undergoing plasma cell–free DNA sequencing. Here, we aimed to determine if the incidental detection of high-risk CH by liquid biopsy may reveal occult hematologic malignancies tumors. MATERIALS AND METHODS Adult advanced cancers enrolled Gustave Roussy Cancer Profiling study (ClinicalTrials.gov identifier: NCT04932525 ) underwent at least one (FoundationOne Liquid CDx). Molecular...
A mesenteric mass (MM), characterized by fibrotic reaction, is present in most small-intestinal neuroendocrine tumors (SI-NETs). <sup>177</sup>Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) has shown its efficacy patients with progressive SI-NETs. However, because of specific tissue characteristics desmoplastic MMs, we hypothesize that these lesions may be refractory to PRRT. <b>Methods:</b> From the national French Groupe d'étude des Tumeurs Endocrines database, identified an...
Vacuolar H+-ATPase-dependent (V-ATPase-dependent) functions are critical for neural proteostasis and involved in neurodegeneration brain tumorigenesis. We identified a patient with fulminant of the developing carrying de novo splice site variant ATP6AP2 encoding an accessory protein V-ATPase. Functional studies induced pluripotent stem cell-derived (iPSC-derived) neurons from this revealed reduced spontaneous activity severe deficiency lysosomal acidification degradation leading to neuronal...
A 59-year-old woman with locally invasive poorly differentiated thyroid cancer synchronous lung, mediastinal, and bone metastases a somatic BRAFK601E mutation contraindication for antiangiogenic drugs was treated dabrafenib trametinib. During treatment, serum levels of thyroglobulin increased as early day 7 up to 10-fold over baseline at week 4. Concurrently, clinical hyperthyroidism occurred, free triiodothyronine thyroxine increasing 6.6 4.4 times their upper reference limit....